BiotechTube
Home/Signpath Pharma/Jonathan Plehn, M.D.
JP

Jonathan Plehn, M.D.

Vice President, Cardiology, Chief Medical Officer

Signpath Pharma

Therapeutic Areas

OncologyCardiology

Signpath Pharma Pipeline

DrugIndicationPhase
LipoCurc™Glioblastoma (First-line treatment)Phase 2
SPP4040 (CorreQT Platform)Prevention of drug-induced cardiotoxicityPreclinical

Leadership Team at Signpath Pharma

KP
Kai P. Larson, J.D.
President, CEO
View full Signpath Pharma profile